These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 15660474

  • 1. Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.
    Grabowski H.
    Pharmacoeconomics; 2004; 22(2 Suppl 2):15-24. PubMed ID: 15660474
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Returns on research and development for 1990s new drug introductions.
    Grabowski H, Vernon J, DiMasi JA.
    Pharmacoeconomics; 2002; 20 Suppl 3():11-29. PubMed ID: 12457422
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Where have all the antibiotic patents gone?
    Katz ML, Mueller LV, Polyakov M, Weinstock SF.
    Nat Biotechnol; 2006 Dec; 24(12):1529-31. PubMed ID: 17160057
    [Abstract] [Full Text] [Related]

  • 9. Decline in economic returns from new drugs raises questions about sustaining innovations.
    Berndt ER, Nass D, Kleinrock M, Aitken M.
    Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
    [Abstract] [Full Text] [Related]

  • 10. Challenges faced by the pharmaceutical industry: training graduates for employment in pharmaceutical R&D.
    Mooney KG.
    Eur J Pharm Sci; 2001 Feb; 12(4):353-9. PubMed ID: 11231101
    [Abstract] [Full Text] [Related]

  • 11. The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution.
    Stegemann S.
    Eur J Pharm Sci; 2016 Jul 30; 90():8-13. PubMed ID: 26542345
    [Abstract] [Full Text] [Related]

  • 12. Revitalizing the patent system to incentivize pharmaceutical innovation: the potential of claims with means-plus-function clauses.
    Tang WL.
    Duke Law J; 2013 Feb 30; 62(5):1069-108. PubMed ID: 25330553
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Patent term extension: an expensive and unnecessary giveaway.
    Gore A.
    Health Aff (Millwood); 1982 Feb 30; 1(2):25-33. PubMed ID: 10621692
    [No Abstract] [Full Text] [Related]

  • 15. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ.
    Drug Discov Today; 2006 Nov 30; 11(21-22):966-74. PubMed ID: 17055405
    [Abstract] [Full Text] [Related]

  • 16. Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development".
    Hollis A.
    Pharmacoeconomics; 2005 Nov 30; 23(12):1187-92; discussion 1193-202. PubMed ID: 16336012
    [No Abstract] [Full Text] [Related]

  • 17. Biotechnology's metamorphosis into a drug discovery industry.
    Drews J.
    Nat Biotechnol; 1998 May 30; 16 Suppl():22-4. PubMed ID: 9591258
    [No Abstract] [Full Text] [Related]

  • 18. Pharmaceutical research: cost savings through innovation.
    Cohen KR, Levy RA.
    AAPPO J; 1993 Oct 30; 3(5):28-36. PubMed ID: 10146463
    [No Abstract] [Full Text] [Related]

  • 19. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV.
    Food Drug Law J; 2007 Oct 30; 62(1):249-56. PubMed ID: 17444032
    [No Abstract] [Full Text] [Related]

  • 20. Settlements between brand and generic pharmaceutical companies: a reasonable antitrust analysis of reverse payments.
    Yvon AM.
    Fordham Law Rev; 2006 Dec 30; 75(3):1883-912. PubMed ID: 17312596
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.